PE20142020A1 - Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek - Google Patents

Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek

Info

Publication number
PE20142020A1
PE20142020A1 PE2014001533A PE2014001533A PE20142020A1 PE 20142020 A1 PE20142020 A1 PE 20142020A1 PE 2014001533 A PE2014001533 A PE 2014001533A PE 2014001533 A PE2014001533 A PE 2014001533A PE 20142020 A1 PE20142020 A1 PE 20142020A1
Authority
PE
Peru
Prior art keywords
inhibitor
methods
treat cancer
pi3k
mek
Prior art date
Application number
PE2014001533A
Other languages
English (en)
Inventor
Karl Hsu
Joanne Lager
Janet Anne Meurer Ogden
Original Assignee
Sanofi Sa
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Merck Patent Gmbh filed Critical Sanofi Sa
Publication of PE20142020A1 publication Critical patent/PE20142020A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN INHIBIDOR DE LA QUINASA PI3K TAL COMO EL COMPUESTO 2-AMINO-8-ETIL-4-METIL-6-(1H-PIRAZOL-5-IL)PIRIDO[2,3-d]PIRIMIDIN-7(8H)-ONA EN UNA CANTIDAD DE 30, 50, 70 O 90MG; Y B) UN INHIBIDOR DE MEK TAL COMO EL COMPUESTO N-((S)-2,3-DIHIDROXIPROPIL)-3-(2-FLUORO-4-YODO-FENILAMINO)ISONICOTINAMIDA EN UNA CANTIDAD DE 15, 30, 60 O 90MG. TAMBIEN SE REFIERE A UN KIT QUE COMPRENDE LA COMPOSICION FARMACEUTICA Y UN ENVASE ADECUADO. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DEL CANCER
PE2014001533A 2012-04-06 2013-04-04 Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek PE20142020A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261621252P 2012-04-06 2012-04-06
FR1351158 2013-02-12
US201361771457P 2013-03-01 2013-03-01

Publications (1)

Publication Number Publication Date
PE20142020A1 true PE20142020A1 (es) 2014-12-24

Family

ID=49301040

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014001533A PE20142020A1 (es) 2012-04-06 2013-04-04 Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek

Country Status (18)

Country Link
US (1) US20150031882A1 (es)
EP (1) EP2854854A1 (es)
JP (1) JP2015515476A (es)
KR (1) KR20150003786A (es)
CN (1) CN104334192A (es)
AU (1) AU2013243429A1 (es)
CA (1) CA2869152A1 (es)
CL (1) CL2014002668A1 (es)
CO (1) CO7121349A2 (es)
CR (1) CR20140480A (es)
DO (1) DOP2014000221A (es)
EA (1) EA201491836A1 (es)
MX (1) MX2014012001A (es)
PE (1) PE20142020A1 (es)
PH (1) PH12014502219A1 (es)
SG (1) SG11201406199TA (es)
TN (1) TN2014000418A1 (es)
WO (1) WO2013152165A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015095829A1 (en) 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of pi3k/akt pathway and erk inhibitors
WO2017065277A1 (ja) * 2015-10-14 2017-04-20 日東紡績株式会社 2種のプロテインキナーゼの活性測定を用いる解析方法による、薬剤感受性ヒト細胞株の判定方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5214971B2 (ja) 2004-10-20 2013-06-19 メルク セローノ ソシエテ アノニム 3−アリルアミノピペリジン誘導体
US8044062B2 (en) * 2005-10-07 2011-10-25 Exelixis, Inc. Substituted pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors of phospatidylinositol 3-kinase alpha
BRPI0617162B8 (pt) 2005-10-07 2021-05-25 Exelixis Inc compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos
JP2013507415A (ja) * 2009-10-12 2013-03-04 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Pi3k阻害剤とmek阻害剤の併用
AR084216A1 (es) * 2010-12-09 2013-05-02 Sanofi Sa Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit

Also Published As

Publication number Publication date
CL2014002668A1 (es) 2015-01-16
TN2014000418A1 (en) 2016-03-30
SG11201406199TA (en) 2014-10-30
PH12014502219A1 (en) 2015-01-12
CA2869152A1 (en) 2013-10-10
JP2015515476A (ja) 2015-05-28
MX2014012001A (es) 2015-05-11
DOP2014000221A (es) 2014-12-15
CN104334192A (zh) 2015-02-04
EA201491836A1 (ru) 2015-02-27
CO7121349A2 (es) 2014-11-20
CR20140480A (es) 2014-11-17
US20150031882A1 (en) 2015-01-29
AU2013243429A1 (en) 2014-10-23
WO2013152165A1 (en) 2013-10-10
KR20150003786A (ko) 2015-01-09
EP2854854A1 (en) 2015-04-08

Similar Documents

Publication Publication Date Title
CL2016001604A1 (es) “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
NI201500067A (es) Compuestos de pirrolopirimidina como inhibidores de quinasa
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
CL2015000829A1 (es) Inhibidores de histona desmetilasas
GT201400196A (es) Compuestos de heterociclilo
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
GT201400009A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
DOP2012000105A (es) Compuestos de espiropiperidina y uso farmaceutico del mismo para tratar la diabetes
NI201500054A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
AR097619A1 (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
EA201591794A1 (ru) Макроциклические ингибиторы соль-индуцируемых киназ
EA201600434A1 (ru) Применение производных бензимидазолпролина
CY1121238T1 (el) Παραγωγα παντοθενικου για την αντιμετωπιση νευρολογικων διαταραχων
UY35332A (es) Derivados de pirrolotriazina como inhibidores de pi3k
DOP2015000176A (es) Compuestos de azetidiniloxifenilpirrolidina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal